Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia.

The I EGR2 i gene, coding for a transcription factor that also mediates the I TP53 i dependent apoptotic pathway, was found to be mutated in 3 patients (8.6%), and further stratifies the outcome of low-risk patients. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. [Extracted from the article]